SELLAS Life Sciences Group, Inc.
SLS
$7.68
-$0.30-3.76%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.86% | -17.50% | -5.44% | -8.74% | -17.13% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.59% | -16.68% | -14.45% | -18.74% | -19.88% |
| Operating Income | -4.59% | 16.68% | 14.45% | 18.74% | 19.88% |
| Income Before Tax | -8.59% | 13.01% | 19.63% | 23.75% | 24.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.59% | 13.01% | 19.63% | 23.75% | 24.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.59% | 13.01% | 19.63% | 23.75% | 24.24% |
| EBIT | -4.59% | 16.68% | 14.45% | 18.74% | 19.88% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 40.54% | 53.56% | 59.67% | 64.84% | 64.97% |
| Normalized Basic EPS | 44.58% | 56.18% | 57.56% | 63.24% | 63.64% |
| EPS Diluted | 39.83% | 53.04% | 59.27% | 64.53% | 64.93% |
| Normalized Diluted EPS | 44.58% | 56.18% | 57.56% | 63.24% | 63.64% |
| Average Basic Shares Outstanding | 81.03% | 78.18% | 82.98% | 103.31% | 117.37% |
| Average Diluted Shares Outstanding | 81.03% | 78.18% | 82.98% | 103.31% | 117.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |